JPH08510221A - Ampa拮抗薬およびそれを用いての治療方法 - Google Patents
Ampa拮抗薬およびそれを用いての治療方法Info
- Publication number
- JPH08510221A JPH08510221A JP6524944A JP52494494A JPH08510221A JP H08510221 A JPH08510221 A JP H08510221A JP 6524944 A JP6524944 A JP 6524944A JP 52494494 A JP52494494 A JP 52494494A JP H08510221 A JPH08510221 A JP H08510221A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- pharmaceutically acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式 〔式中、R1は水素、アルキルまたはベンジルであり; XはOまたはNOR2(但し、R2は水素、アルキルまたはベンジルであ る)であり; YはN−R4(但し、R4 は水素、OH又はアルキルである)であり; nは0または1であり; R6 はフェニル、 ナフチル、 チエニル、 ピリジル (但し、これらのすべては、ハロゲン、CF3、NO2 、アミノ、ア ルキル、アルコキシおよびフェニルからなる群から選ばれた置換基で1回または それ以上の回数で置換されていてもよい)であり; Aはaおよびbのマークでマークされた位置でベンゾ環と縮合された5 〜7個の原子の環でありそして次の二価の基により形成される: a−NR12−CH2 −CH2 −b a−CH2 −CH2 −NR12−b a−CH2 −NR12−CH2 −b, a−CH2 −CH2 −NR12−CH2 −b, a−CH2 −NR12−CH2 −CH2 −b, a−CH2 −CH2 −CH2 −NR12−b, a−NR12−CH2 −CH2 −CH2 −b, a−CH2 −CH2 −NR12−CH2 −CH2 −b, a−CH2 −CH2 −CH2 −NR12−CH2 −b, a−CH2 −NR12−CH2 −CH2 −CH2 −b, a−CH2 −CH2 −CH2 −CH2 −NR12−b, a−NR12−CH2 −CH2 −CH2 −CH2 −b, (但しR12は水素、CH2CH2OHまたはアルキルである)〕 を有する化合物またはその製薬的に許容出来る塩。 2.式 (式中、X、Y、n、R1、R6およびR12は請求項1において記載された意味を 有する)を有する、請求項1の化合物またはその製薬的に許容出来る塩。 3.式 (式中、X、Y、n、R1、R6およびR12は請求項1において記載された意味を 有する)を有する、請求項1の化合物またはその製薬的に許容出来る塩。 4.式 (式中、X、Y、n、R1、R6およびR12は請求項1において記載された意味を 有する)を有する、請求項1の化合物またはその製薬的に許容出来る塩。 5.式 (式中、X、Y、n、R1、R6およびR12は請求項1において記載された意味を 有する)を有する、請求項1の化合物またはその製薬的に許容出来る塩。 6.単位投与量形態で請求項1の化合物の有効量を、その必要に応じて患者に 投与することからなる、病気または障害がグルタミン酸および(または)アスパ ラギン酸受容体の阻害に応答性である、ヒトを包含する哺乳動物の病気または障 害を治療する方法。 7.ラチリスム、アルツハイマー病、ハンチントン病、ALS、***症、パー キンソン症、てんかん、不安症、疼痛、薬剤依存症または脳血管障害が治療され る、請求項6の方法。 8.製薬的に許容出来る担体と一緒に請求項1の化合物の治療的に有効な量を 含む製薬組成物。 9.病気または障害がグルタミン酸および(または)アスパラギン酸受容体の 封鎖に応答性である、ヒトを包含する哺乳動物の病気または障害を治療するため の医薬を製造するための請求項1の化合物の使用。 10.(a)式 (式中、A、a、b、R1およびR6は請求項1において記載された意味を有する )を有する化合物を NH2OR2 (式中、R2は請求項1において記載された意味を有する)とまたはその反応性 誘導体と反応させて請求項1の化合物を形成するか、または (b)式 (式中、A、a、b、R1およびR6は上に記載された意味を有する)を有する化 合物を、しゅう酸またはその反応性誘導体と反応させて請求項1の化合物を形成 する、工程からなる請求項1の化合物の製造方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK55893A DK55893D0 (da) | 1993-05-13 | 1993-05-13 | Nye receptoraktive forbindelser, deres fremstilling og anvendelse |
DK0138/94 | 1994-02-02 | ||
DK13894 | 1994-02-02 | ||
DK0558/93 | 1994-02-02 | ||
PCT/EP1994/001492 WO1994026747A1 (en) | 1993-05-13 | 1994-05-09 | Ampa antagonists and a method of treatment therewith |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08510221A true JPH08510221A (ja) | 1996-10-29 |
JP3439215B2 JP3439215B2 (ja) | 2003-08-25 |
Family
ID=26063386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52494494A Expired - Fee Related JP3439215B2 (ja) | 1993-05-13 | 1994-05-09 | Ampa拮抗薬およびそれを用いての治療方法 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0698025B1 (ja) |
JP (1) | JP3439215B2 (ja) |
AT (1) | ATE161259T1 (ja) |
AU (1) | AU679075B2 (ja) |
CA (1) | CA2161783C (ja) |
DE (1) | DE69407407T2 (ja) |
DK (1) | DK0698025T3 (ja) |
ES (1) | ES2111930T3 (ja) |
FI (1) | FI954965A (ja) |
GR (1) | GR3026008T3 (ja) |
NO (1) | NO305287B1 (ja) |
NZ (1) | NZ267081A (ja) |
WO (1) | WO1994026747A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597922A (en) * | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
WO1996028445A1 (en) * | 1995-03-14 | 1996-09-19 | Warner-Lambert Company | Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones |
US5566694A (en) * | 1995-06-07 | 1996-10-22 | Allegheny Plastics, Inc. | Continuous pickling tank with expandable seals |
US6110911A (en) * | 1995-06-07 | 2000-08-29 | Warner-Lambert Company | Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US5874426A (en) * | 1995-06-07 | 1999-02-23 | Warner-Lambert Company | Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US5654303A (en) * | 1995-06-07 | 1997-08-05 | Warner-Lambert Company | Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
US5614508A (en) * | 1995-06-07 | 1997-03-25 | Warner-Lambert Company | Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
US5773434A (en) * | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
UA54403C2 (uk) * | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму |
WO1998027097A1 (en) * | 1996-12-16 | 1998-06-25 | Warner-Lambert Company | Tricyclic quinoxaline derivatives as neuroprotective agents |
US6172065B1 (en) | 1997-03-04 | 2001-01-09 | Warner-Lambert Company | Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
DE69922936T2 (de) | 1998-03-31 | 2005-12-08 | Neurosearch A/S | Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten |
US6096744A (en) * | 1998-05-04 | 2000-08-01 | Warner-Lambert Company | Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
ATE420636T1 (de) | 1999-05-19 | 2009-01-15 | Painceptor Pharma Corp | Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen |
DK1255734T3 (da) | 2000-01-24 | 2006-10-09 | Neurosearch As | Hidtil ukendte isatin-derivater |
DE10121215A1 (de) | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
CA2630617C (en) | 2005-11-23 | 2014-03-25 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
EP2010497A1 (en) * | 2006-04-10 | 2009-01-07 | PainCeptor Pharma Corp. | Compositions and methods for modulating gated ion channels |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK146787A (da) * | 1987-03-23 | 1988-09-24 | Ferrosan | Heterocykliske forbindelser, deres fremstilling og anvendelse |
MX9204914A (es) * | 1991-08-28 | 1993-07-01 | Frank Watjen | Nuevos derivados de isatinoxima, metodo para su preparacion y composicion farmaceutica que los comprende. |
ATE157977T1 (de) * | 1992-10-13 | 1997-09-15 | Warner Lambert Co | Chinoxalinderivate als eaa antagonisten |
-
1994
- 1994-05-09 ES ES94917602T patent/ES2111930T3/es not_active Expired - Lifetime
- 1994-05-09 WO PCT/EP1994/001492 patent/WO1994026747A1/en active IP Right Grant
- 1994-05-09 NZ NZ267081A patent/NZ267081A/en not_active IP Right Cessation
- 1994-05-09 DE DE69407407T patent/DE69407407T2/de not_active Expired - Lifetime
- 1994-05-09 DK DK94917602T patent/DK0698025T3/da active
- 1994-05-09 EP EP94917602A patent/EP0698025B1/en not_active Expired - Lifetime
- 1994-05-09 CA CA002161783A patent/CA2161783C/en not_active Expired - Fee Related
- 1994-05-09 AT AT94917602T patent/ATE161259T1/de not_active IP Right Cessation
- 1994-05-09 JP JP52494494A patent/JP3439215B2/ja not_active Expired - Fee Related
- 1994-05-09 AU AU69264/94A patent/AU679075B2/en not_active Ceased
-
1995
- 1995-10-18 FI FI954965A patent/FI954965A/fi unknown
- 1995-11-13 NO NO954576A patent/NO305287B1/no not_active IP Right Cessation
-
1998
- 1998-01-28 GR GR980400178T patent/GR3026008T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2161783A1 (en) | 1994-11-24 |
ATE161259T1 (de) | 1998-01-15 |
JP3439215B2 (ja) | 2003-08-25 |
AU6926494A (en) | 1994-12-12 |
FI954965A (fi) | 1995-11-10 |
NO954576L (no) | 1996-01-15 |
GR3026008T3 (en) | 1998-04-30 |
DK0698025T3 (da) | 1998-08-24 |
EP0698025B1 (en) | 1997-12-17 |
AU679075B2 (en) | 1997-06-19 |
CA2161783C (en) | 2006-08-15 |
WO1994026747A1 (en) | 1994-11-24 |
DE69407407D1 (de) | 1998-01-29 |
FI954965A0 (fi) | 1995-10-18 |
ES2111930T3 (es) | 1998-03-16 |
NZ267081A (en) | 1997-11-24 |
EP0698025A1 (en) | 1996-02-28 |
NO305287B1 (no) | 1999-05-03 |
NO954576D0 (no) | 1995-11-13 |
DE69407407T2 (de) | 1998-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08510221A (ja) | Ampa拮抗薬およびそれを用いての治療方法 | |
JP4685243B2 (ja) | ピリミド[6,1−a]イソキノリン−4−オン誘導体 | |
RU2190612C2 (ru) | Новые производные индол-2,3-дион-3-оксима | |
JPH0311067A (ja) | 興奮性アミノ酸拮抗剤 | |
JP3164372B2 (ja) | 融合インドール及びキノキサリン誘導体、その製造および使用 | |
DE69922936T2 (de) | Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten | |
US5843945A (en) | AMPA antagonists and a method of treatment | |
JP3164371B2 (ja) | インドール−2,3−ジオン−3−オキシム誘導体、その製造および使用 | |
AU765213B2 (en) | Tetrahydroindazole derivatives as ligands for gaba-a alpha 5 receptors | |
JP2956788B2 (ja) | スピロイソインドリン化合物、その製造方法、それを含有する神経症を治療するための医薬およびそれを製造するための中間体 | |
JPH09508917A (ja) | フェニルピロール誘導体およびそのドーパミンd▲下3▼アンタゴニストとしての使用 | |
MXPA06004486A (es) | Azabenzodiazepinas como inhibidores de fosfodiesterasa-4. | |
JPH11504616A (ja) | ジベンズ[cd,f]インドール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080613 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090613 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100613 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 8 |
|
LAPS | Cancellation because of no payment of annual fees |